Merck KGaA (MRCG.DE) Key Developments | Reuters.com
Edition:
United States

Merck KGaA (MRCG.DE)

MRCG.DE on Xetra

90.31EUR
10:13am EDT
Change (% chg)

€-0.05 (-0.06%)
Prev Close
€90.36
Open
€90.25
Day's High
€90.66
Day's Low
€89.30
Volume
192,904
Avg. Vol
553,958
52-wk High
€98.82
52-wk Low
€70.68

Latest Key Developments (Source: Significant Developments)

Merck KGaA says plans to apply for authorization for Avelumab in H2
Monday, 20 Jun 2016 05:00am EDT 

Merck Kgaa : Says plan to apply for marketing authorization for avelumab against merkel cell carcinoma in h2 2016 Further company coverage: [MRCG.DE] ((frankfurt.newsroom@thomsonreuters.com; +49 69 7565 1272;)).  Full Article

Merck KGaA partners with Array BioPharma, Pierre Fabre on mCRC phase iii trial
Saturday, 4 Jun 2016 09:23am EDT 

Merck KGaA : Says partners with Array BioPharma and Pierre Fabre to initiate braf-mutant mCRC phase iii trial Further company coverage: [MRCG.DE] ((frankfurt.newsroom@thomsonreuters.com; +496975651270;)).  Full Article

Merck KGaA publishes Chinese Phase III study for Erbitux - Reuters
Monday, 25 Apr 2016 02:11am EDT 

Merck KGaA:Says phase III tailor landmark study demonstrates significant benefits of erbitux in combination with folfox over folfox alone - Reuters.Says marks a major milestone of merck’s oncology strategy including expansion in growth markets.Says will work with relevant authorities to make erbitux available for patients in china as a first - line treatment as soon as possible.  Full Article

Merck KGaA issues FY 2016 outlook, to propose FY 2015 dividend
Tuesday, 8 Mar 2016 01:00am EST 

Merck KGaA:Expects slight organic sales growth in 2016, low double-digit pct increase in adjusted EBITDA.Proposes annual dividend of 1.05 euros per share vs poll avg of 1.09 euros per share.FY 2016 revenue 15,310 million euros - Thomson Reuters I/B/E/S.FY 2016 EBITDA 4,314 million euros - Thomson Reuters I/B/E/S.  Full Article

Merck KGaA, Darmstadt, Germany, Pfizer and Verastem announce combination trial of Avelumab and VS-6063 in ovarian cancer
Thursday, 3 Mar 2016 07:00am EST 

Merck KGaA Merck KGaA, Darmstadt, Germany, Pfizer and Verastem:Says have entered into an agreement to evaluate avelumab, an investigational fully human anti-PD-L1 IgG1 monoclonal antibody, in combination with Verastem's VS-6063, an investigational focal adhesion kinase inhibitor, in patients with advanced ovarian cancer.Financial terms of the agreement have not been disclosed.Phase I/Ib clinical trial is expected to begin in the second half of 2016.  Full Article

Merck KGaA and Biocartis to collaborate on new liquid biopsy technology for RAS biomarker testing
Wednesday, 6 Jan 2016 07:00pm EST 

Merck KGaA:Merck and Biocartis to collaborate on new liquid biopsy technology for RAS biomarker testing.Merck becomes first pharmaceutical company to collaborate with multiple diagnostic providers to support RAS biomarker testing.Collaboration allows Merck to provide complementary molecular testing solutions to various laboratory segments.  Full Article

Merck KGaA,Darmstadt, Germany, Pfizer and Syndax announces collaboration to evaluate combination of avelumab and entinostat in ovarian cancer
Monday, 4 Jan 2016 08:00am EST 

Merck KGaA:Says Co, Darmstadt, Germany, Pfizer and Syndax announces collaboration to evaluate combination of avelumab and entinostat in ovarian cancer.Says financial terms of the agreement were not disclosed.This is an exclusive agreement between the alliance and syndax to study the combination of two investigational agents in ovarian cancer.Says syndax will be responsible for conducting the phase ib/ii clinical trial in ovarian cancer.  Full Article

Merck KGaA acquires Ormet Circuits, no purchase price disclosed
Sunday, 13 Dec 2015 07:00pm EST 

Merck KGaA:Acquires Ormet Circuits, no purchase price disclosed.Says acquisition to enhance position as semiconductor materials supplier.Merck says deal complements existing integrated circuit materials business unit.  Full Article

Merck KGaA to invest extra 250 million euros in pharma pipeline
Wednesday, 9 Dec 2015 07:00pm EST 

Merck KGaA:Plans to invest extra 250 million euros in pharma pipeline.Sees one-off integration costs from sigma-aldrich of 400 million euros over 4 yrs.Expects cost savings of 90 million euros from sigma-aldrich takeover‍​.  Full Article

Merck KGaA, Threshold drug fails in late-stage cancer trials - Reuters
Sunday, 6 Dec 2015 10:11pm EST 

Merck KGaA:Merck KGaA MRCG.DE and development partner Threshold Pharmaceuticals THLD.O said their experimental cancer drug evofosfamide failed to extend lives in two late-stage clinical studies, a major setback for both firms - RTRS.Evofosfamide did not meet the main goal of improving survival in patients suffering from advanced pancreatic cancer and advanced soft tissue sarcoma, prompting the two companies to give up exploring the drug's use against these cancer forms. - RTRS.Merck said on Monday it would focus efforts on more promising candidates in its drug pipeline and would soon decide about evofosfamide's overall future - RTRS.The new disappointment leaves CEO-designate Stefan Oschmann, a pharmaceuticals expert, with a narrow drug development pipeline that rests mainly on cancer immune therapy avelumab, jointly developed with Pfizer - RTRS.  Full Article

BRIEF-Merck KGaA says plans to apply for authorization for Avelumab in H2

* Says plan to apply for marketing authorization for avelumab against merkel cell carcinoma in h2 2016 Further company coverage: